Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026)

MoonLake Immunotherapeutics' Operating Leases history spans 5 years, with the latest figure at $865000.0 for Q1 2026.

  • Quarterly Operating Leases fell 24.26% to $865000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $865000.0 through Mar 2026, down 24.26% year-over-year, with the annual reading at $374000.0 for FY2025, 74.35% down from the prior year.
  • Operating Leases came in at $865000.0 for Q1 2026, up from $374000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.4 million in Q3 2024 to a low of $91081.0 in Q1 2023.
  • The 5-year median for Operating Leases is $1.3 million (2024), against an average of $1.4 million.
  • Year-over-year, Operating Leases soared 2488.35% in 2024 and then crashed 74.35% in 2025.
  • MoonLake Immunotherapeutics' Operating Leases stood at $128951.0 in 2022, then skyrocketed by 1838.71% to $2.5 million in 2023, then tumbled by 41.68% to $1.5 million in 2024, then plummeted by 74.35% to $374000.0 in 2025, then surged by 131.28% to $865000.0 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Operating Leases are $865000.0 (Q1 2026), $374000.0 (Q4 2025), and $2.0 million (Q3 2025).